Experts explain how longer-lasting anti-VEGF injections reduce treatment burden and improve real-world vision outcomes in AMD ...

Real-world anti‑VEGF outcomes lag trials as durability and missed injections matter; learn how evidence guides everyday wet AMD decisions. In this episode, “Role of Anti-VEGF Real-World Evidence in ...

Investigators led by Tsutomu Kume, Ph.D., professor of Medicine in the Division of Cardiology and of Pharmacology, have identified novel genetic mechanisms that regulate blood vessel growth in the ...

Obstructive sleep apnea (OSA) was associated with a notably higher risk of developing retinal vein occlusion across different demographic groups, with the greatest increase observed in people of ...

This activity has been designed to meet the educational needs of retina specialists, ophthalmologists, and other clinicians who are interested in the management of patients with retinal vascular ...

New research has found that the endothelial cell-specific A disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) regulates abnormal blood vessel growth in the damaged retina, which ...

Researchers at Johns Hopkins University have identified a process in the eye that may explain why biologic drugs for treating age-related macular degeneration (AMD) fail in some patients. Using that ...

European commercialization introduces an additional aflibercept biosimilar option for major retinal indications, potentially ...

Gpr124 represents a promising novel target for improving the integrity and function of the blood-retina barrier (BRB) with the goal of slowing, halting, preventing or even reversing vision loss ...

Ocugen OCGN is advancing a retinal pipeline built around durability and breadth. Its focus is a modifier gene therapy ...